Oncoinvent ASA (OSL:ONCIN)

Market Cap	215.86M
Revenue (ttm)	28.07M +246.4%
Net Income	-155.07M
EPS	-1.25
Shares Out	4.48M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,492
Average Volume	5,860
Open	49.70
Previous Close	48.20
Day's Range	47.10 - 49.70
52-Week Range	40.10 - 134.80
Beta	n/a
RSI	54.00
Earnings Date	Apr 22, 2026

About Oncoinvent ASA

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Oystein Soug
• Employees: 36
• Stock Exchange: Oslo Børs
• Ticker Symbol: ONCIN

Financial Performance

In 2025, Oncoinvent ASA's revenue was 28.07 million, an increase of 246.40% compared to the previous year's 8.10 million. Losses were -155.07 million, 10.6% more than in 2024.